Best Peptides for Sexual Health — Evidence Review
Sexual health peptides target the central — desire, arousal, motivation — rather than the peripheral. The peptide with the most clinical evidence is PT-141 (bremelanotide), FDA-approved for…
Sexual health peptides target the central — desire, arousal, motivation — rather than the peripheral. The peptide with the most clinical evidence is PT-141 (bremelanotide), FDA-approved for hypoactive sexual desire disorder in premenopausal women and used off-label for erectile dysfunction in men.
Peptides with FDA approval and strongest data
PT-141 (Bremelanotide / Vyleesi)
FDA-approved as Vyleesi for HSDD in premenopausal women. Used off-label for ED in men.
Mechanism: melanocortin-4 receptor agonist with central action on sexual desire and arousal. This is mechanistically distinct from PDE5 inhibitors (sildenafil, tadalafil) — it works on the desire side rather than the mechanical side. Some patients who don't respond to PDE5 inhibitors respond to PT-141.
Side effect profile is significant. Nausea is the most common (~40% in trials). Hypertensive episodes are documented and concerning in cardiovascular disease — FDA prescribing information lists CV disease as a contraindication. Skin hyperpigmentation can occur with frequent use.
Full PT-141 profile → | Bremelanotide overview →
Supporting cast — research stage
Kisspeptin
Hypothalamic peptide regulating GnRH and the HPG axis. Research interest in male sexual function (via testosterone-axis modulation) and in female sexual function. Clinical applications are still in research stages.
Oxytocin
Often discussed in pair-bonding and intimacy contexts. Intranasal oxytocin's CNS penetration and behavioral relevance is contested in the literature. Effect sizes in trials are modest.
What the evidence does not support
- BPC-157, TB-500, or tissue-repair peptides for sexual function
- GH secretagogues (CJC-1295, ipamorelin) for libido or sexual performance
- Peptide therapy as a substitute for evaluation of underlying causes — testosterone deficiency, vascular disease, depression, medication side effects, and relationship factors are the most common drivers
- Use of PT-141 in significant cardiovascular disease
Important practical considerations
For ED specifically, ED is frequently the earliest symptom of cardiovascular disease. New-onset ED in men over 40 warrants cardiovascular evaluation, not immediate peptide therapy.
For female sexual dysfunction, comprehensive evaluation should rule out hormonal causes, depression, medication side effects, and relationship-context factors before pharmacology.
PT-141 should not be stacked with PDE5 inhibitors without clinical guidance — combined effects on blood pressure are not well-characterized.
Where to source
- PT-141 vendor rankings — limited; PT-141 has fewer ranked vendors than the metabolic-peptide class
What we don't know
- Long-term safety of PT-141 in repeated use beyond clinical-trial timelines
- Whether kisspeptin will mature into a clinically useful sexual medicine therapy
- Optimal patient selection between PDE5 inhibitors and PT-141 in mixed mechanism ED
- Effect sizes of oxytocin in real-world use
Methodology
Read the full methodology.
This page is educational. Sexual health concerns benefit from proper evaluation, including cardiovascular and endocrine assessment as appropriate. PDE5 inhibitors remain first-line for most ED; PT-141 is a second-line option with a narrower safety window.